Shots: Denali to get $125M upfront plus milestones payments that can exceed $1B and will also receive royalties for DNL747 (ex-US & China) & DNL758 (WW). The profit/loss sharing will be divided equally and this partnership also includes pre-clinical RIPK1 inhibitor candidate Sanofi will fund DNL747 (P-Ib & P-II) & DNL747 in MS (multiple sclerosis), […]Read More
